THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 23 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $4,614,000 | -14.6% | 4,960,000 | -9.8% | 0.10% | -1.0% |
Q1 2022 | $5,405,000 | +1.7% | 5,500,000 | 0.0% | 0.10% | -5.4% |
Q4 2021 | $5,313,000 | +2.5% | 5,500,000 | 0.0% | 0.11% | -6.7% |
Q3 2021 | $5,182,000 | -1.6% | 5,500,000 | 0.0% | 0.12% | +4.4% |
Q2 2021 | $5,264,000 | -7.3% | 5,500,000 | 0.0% | 0.11% | -21.9% |
Q1 2021 | $5,680,000 | +8.0% | 5,500,000 | 0.0% | 0.15% | -1.4% |
Q4 2020 | $5,257,000 | +5.7% | 5,500,000 | 0.0% | 0.15% | -22.1% |
Q3 2020 | $4,973,000 | -7.7% | 5,500,000 | 0.0% | 0.19% | -21.8% |
Q2 2020 | $5,385,000 | -2.8% | 5,500,000 | 0.0% | 0.24% | -9.7% |
Q1 2020 | $5,538,000 | +103.6% | 5,500,000 | +175.0% | 0.27% | +8.0% |
Q2 2017 | $2,720,000 | -57.6% | 2,000,000 | -60.0% | 0.25% | -61.9% |
Q1 2017 | $6,412,000 | -38.4% | 5,000,000 | -44.4% | 0.65% | -33.8% |
Q4 2016 | $10,407,000 | – | 9,000,000 | – | 0.99% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Context Capital Management, LLC | 13,473,000 | $12,756,000 | 1.74% |
Shaolin Capital Management LLC | 14,065,000 | $13,281,000 | 0.93% |
ZAZOVE ASSOCIATES LLC | 3,773,000 | $3,584,000 | 0.44% |
FARALLON CAPITAL MANAGEMENT LLC | 56,695,000 | $53,806,000 | 0.32% |
Baupost Group | 30,000,000 | $28,396,000 | 0.26% |
Aequim Alternative Investments LP | 3,000,000 | $2,840,000 | 0.21% |
WOLVERINE ASSET MANAGEMENT LLC | 24,100,000 | $22,817,000 | 0.17% |
TENOR CAPITAL MANAGEMENT Co., L.P. | 5,500,000 | $5,257,000 | 0.15% |
SSI INVESTMENT MANAGEMENT LLC | 1,750,000 | $1,648,000 | 0.12% |
GABELLI & Co INVESTMENT ADVISERS, INC. | 430,000 | $406,000 | 0.06% |